Our research and clinical trials have made us a leader in improving survival rates for hard-to-treat pediatric brain tumors like medulloblastoma and atypical teratoid rhabdoid tumor (ATRT). We also were the first pediatric hospital to install a mobile “intraoperative MRI,” which allows surgeons to obtain images while the patient is still under anesthesia and to perform further procedures as needed.
This is a 2-part study to determine the safety, tolerability and the interactions within the body of oral dabrafenib in children with advanced BRAF V600 mutation-positive solid tumors – including pediatric low-grade gliomas (LGG), pediatric high-grade gliomas (HGG), Langerhans cell histiocytosis (LCH), melanoma, papillary thyroid carcinoma (PTC), and other tumors. In Part 1, patients received a starting dose of 3 mg/kg. That dose was escalated until we identified the optimal dose in both young children and adolescents. Part 2 consists of four disease-specific cohorts (LGG, HGG, LCH and all others) of subjects with tumors known to have BRAF V600 activation. Each cohort is enrolling at least 10 patients using the optimal dose that was defined in Part 1.
PI: Mark W. Kieran, MD, PhD
Search for pediatric brain tumor clinical trials by condition using the links below, or download a summary of all current trials at Dana-Farber/Boston Children's Cancer and Blood Disorders Center.